Journal of Immunotherapy with Emphasis on Tumor Immunology
about
Delivery of cytokines by liposomes. II. Interleukin-2 encapsulated in long-circulating sterically stabilized liposomes: immunomodulatory and anti-tumor activity in mice.Eisenin (L-pyroGlu-L-Gln-L-Ala), a new biological response modifier.Influence of biological response modifiers: measurement of tumor blood flow and temperature.Low-dose rIL-2-induced remission of disseminated CD30+ anaplastic large-cell lymphoma through reinforcement of presumed T-cell-mediated tumor cell killing, complicated by unilateral drowning of lymphoma-infiltrated lung.Anti-tumor activity of cytotoxic T lymphocytes elicited with recombinant and synthetic forms of a model tumor-associated antigen.T-cell recognition of human melanoma antigensMolecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I.Defective major histocompatibility complex class I expression in a sarcomatoid renal cell carcinoma cell line.Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell linesHLA associations in the antitumor response against malignant melanoma.Enhanced susceptibility of c-myc antisense oligonucleotide-treated human renal cell carcinoma cells to lysis by peripheral blood lymphocytes.A human T cell line engineered to secrete chimeric monoclonal antibody.Hematologic and immunologic evaluation of recombinant human interleukin-6 in patients with advanced malignant disease: evidence for monocyte activation.Treatment of stage IIIB non-small-cell lung cancer with surgery followed by infusion of tumor infiltrating lymphocytes and recombinant interleukin-2: a pilot study.A phase II trial of interleukin-2 and interferon-alpha in the treatment of metastatic colorectal carcinoma.Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer.A phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study.Phase I clinical trial in cancer patients of a new monoclonal antibody FC-2.15 reacting with tumor proliferating cells.Phase II trial of recombinant interleukin-1 beta in patients with metastatic renal cell carcinoma.Subcutaneously administered recombinant interferon-gamma in humans: pharmacokinetics and effects on chemiluminescence responses of alveolar macrophages, blood neutrophils, and monocytes.Phase I trial of cisplatin, WR-2721, and the murine monoclonal antibody R24 in patients with metastatic melanoma: clinical and biologic effects.A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study.Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial.Human immune response to monoclonal antibodies.Adverse reactions to intravenous contrast media in patients treated with interleukin-2.Evidence for activation of the sympathetic nervous system by recombinant human interleukin-1 beta in humans.Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma.A pilot phase II trial of continuous-infusion interleukin-2 followed by lymphokine-activated killer cell therapy and bolus-infusion interleukin-2 in renal cancer.Genes coding for tumor antigens recognized by human cytolytic T lymphocytes.Cytokine-induced tumor immunogenicity: from exogenous cytokines to gene therapy.Activation of multiple effector mechanisms to enhance tumor immunotherapy.Antigen processing: where tumor-specific T-cell responses begin.Role of T-cell tolerance in the persistence of hepatitis B virus infection.HLA class I antigens in Japanese patients with melanoma.A phase I trial of intravenous interleukin-6 in patients with advanced cancer.T-cell retargeting using bispecific monoclonal antibodies in a rat colon carcinoma model: IV. Tumor neutralization in Winn type assays.Adoptive immunotherapy involving recombinant human M-CSF and R24 anti-melanoma antibody induces human T-cell infiltration into human melanoma xenografts.Analysis of expression of the melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and in in situ lesions.Murine cells transfected with human Hsp27 cDNA resist TNF-induced cytotoxicity.
P1433
Q33490050-387C62C8-B4F7-4F56-B931-D1A57A656BDFQ34360605-A51AAAF4-1F69-42B6-A0CD-0696E0F3F324Q36713679-48BE3302-4397-4DA1-BAF9-A985BDD450ABQ36810435-40894F14-A731-4CBF-9D1D-E1F5C7B8E832Q36914397-2694A53A-4325-43C0-A3EF-CF11FAC5DED0Q36914400-69FF4330-29B4-4201-AF53-C48C8FFC7D29Q36914404-17CEECEC-B15E-4D71-9178-6C74FF59FFC6Q36916513-4F47E457-7447-42E7-BEFD-31CA5DFE20E5Q36922798-37749048-DE42-44F1-9C1A-95061C006070Q36924466-D32D837E-F9F8-4EC6-B2C8-6BF8E0BC8CA8Q38299385-3E9B7746-E3F3-416B-B0B4-CE349627B39CQ38565572-1772EF0D-DF49-46B0-8F70-E1E9652D885DQ40668813-2826D836-2DC2-4F25-971B-3E4DE14AA46AQ40668820-58026EF4-D029-4856-A767-DAAFF87707C4Q40677989-30642866-121E-4ED0-98E3-822AE66A15A4Q40679085-7224946E-2621-4E68-9380-01E02D44F6BFQ40681541-49C0E3EA-1BA2-47E5-AB9F-D91D4A548F54Q40687101-77526585-F19F-49B9-9DBF-3CF507D740F6Q40695650-9F6A2A1C-82D4-4563-860A-74A98BA1A0D5Q40701242-41054AFD-301C-432E-AB67-35E08CD69508Q40701247-77AF34D9-15B2-43FB-BD0C-E9EBD8D0775BQ40702633-6B83FA6B-498B-454A-894E-0573E3F92BB2Q40705330-DE391126-0DE3-4AED-83C0-33252DE7BEDAQ40705334-4942A261-94E1-4B1E-AD27-8A47C007A953Q40716264-9453A39E-3D45-426F-A77F-12DD05BE33DBQ40719316-5F1A0421-6B3F-43A8-ACA8-7349057B5262Q40722093-5F5B15CB-2264-4286-AF83-A1677FE6AFBFQ40722100-0FDFC7F7-1F5E-4C6C-BFB7-FAD9D4F0A289Q40723197-F95E59F4-73F6-4D55-BC3A-BBD74F3D32D8Q40800713-A281D8A2-C04B-42B5-B8B3-3565B4EB11DBQ40800721-EF018237-9F3F-489A-B69F-E50356EFB48CQ40800726-59DAB2AE-E237-433C-87AD-BDF0D962F9A4Q40809310-52D96D43-96FD-43B6-931B-F4123D9876D1Q40809317-0B0CA99B-39BE-4767-93E3-6EB11E07689AQ40920936-BE64E14F-E302-4902-95E7-4254ACF1F510Q41035933-02855D76-671A-4B43-9A40-0361692EB2A2Q41073907-45A0A433-1DF3-4C82-B3F4-3503BA5872CBQ41169616-AFA722CB-C750-4501-9817-87F968E0547AQ41200467-E9AA1013-7DFC-4CA1-9637-825AC24885FAQ41242172-F4D70B9E-70D9-4F50-AA99-BA1D5C8755B7
P1433
Journal of Immunotherapy with Emphasis on Tumor Immunology
description
czasopismo naukowe
@pl
revista científica
@es
revue scientifique
@fr
rivista scientifica
@it
scientific journal. Official journal of the Society for Biological Therapy
@en
wetenschappelijk tijdschrift
@nl
wissenschaftliche Fachzeitschrift
@de
name
Journal of Immunotherapy with Emphasis on Tumor Immunology
@ast
Journal of Immunotherapy with Emphasis on Tumor Immunology
@de
Journal of Immunotherapy with Emphasis on Tumor Immunology
@en
Journal of Immunotherapy with Emphasis on Tumor Immunology
@es
Journal of Immunotherapy with Emphasis on Tumor Immunology
@fr
Journal of Immunotherapy with Emphasis on Tumor Immunology
@it
Journal of immunotherapy with ...... Society for Biological Therapy
@nl
type
label
Journal of Immunotherapy with Emphasis on Tumor Immunology
@ast
Journal of Immunotherapy with Emphasis on Tumor Immunology
@de
Journal of Immunotherapy with Emphasis on Tumor Immunology
@en
Journal of Immunotherapy with Emphasis on Tumor Immunology
@es
Journal of Immunotherapy with Emphasis on Tumor Immunology
@fr
Journal of Immunotherapy with Emphasis on Tumor Immunology
@it
Journal of immunotherapy with ...... Society for Biological Therapy
@nl
altLabel
J Immunother Emphasis Tumor Immunol
@en
prefLabel
Journal of Immunotherapy with Emphasis on Tumor Immunology
@ast
Journal of Immunotherapy with Emphasis on Tumor Immunology
@de
Journal of Immunotherapy with Emphasis on Tumor Immunology
@en
Journal of Immunotherapy with Emphasis on Tumor Immunology
@es
Journal of Immunotherapy with Emphasis on Tumor Immunology
@fr
Journal of Immunotherapy with Emphasis on Tumor Immunology
@it
Journal of immunotherapy with ...... Society for Biological Therapy
@nl
P1055
P1156
P1476
Journal of Immunotherapy with Emphasis on Tumor Immunology
@en